Abstract
Radiation therapy controls local disease but also prompts the release of tumor-associated antigens and stress-related danger signals that primes T cells to promote tumor regression at unirradiated sites known as the abscopal effect. This may be enhanced by blocking inhibitory immune signals that modulate immune activity through a variety of mechanisms. Indeed, abscopal responses have occurred in patients with lung cancer or melanoma when given anti-CTLA4 antibody and radiation. Other approaches involve expanding and reinfusing T or NK cells or engineered T cells to express receptors that target specific tumor peptides. These approaches may be useful for immunocompromised patients receiving radiation. Preclinical and clinical studies are testing both immune checkpoint-based strategies and adoptive immunotherapies with radiation.
Original language | English (US) |
---|---|
Pages (from-to) | 967-980 |
Number of pages | 14 |
Journal | Immunotherapy |
Volume | 7 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2015 |
Keywords
- CAR T cells
- OX40
- abscopal effect
- immune checkpoints
- immunotherapy
- ipilimumab
- lung cancer
- melanoma
- nivolumab
- radiation
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology